What this is
- This research investigates the prevalence of symptoms and comorbidities in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
- It focuses on the presence of and platelet pathology as potential contributors to these symptoms.
- Data were collected from a South African Long COVID registry and blood samples were analyzed for platelet and microclot pathology.
Essence
- and are prevalent in individuals with . A grading system for these pathologies may aid in diagnosis.
Key takeaways
- and were observed in all 80 patients diagnosed with . These changes may contribute to persistent symptoms post-COVID-19.
- Hypertension, high cholesterol, and type-2 diabetes are significant comorbidities in the cohort of 845 patients. These comorbidities may influence the severity and persistence of symptoms.
- A platelet and microclot grading system was developed to classify the severity of platelet and microclot pathologies. This system could facilitate early diagnosis and treatment of .
Caveats
- The study's reliance on self-reported symptoms may introduce bias. Objective measures of symptom severity were not uniformly applied.
- The cohort size for blood sample analysis was limited to 80 patients, which may affect the generalizability of the findings.
- No clinical trials have been conducted to evaluate treatment protocols for , highlighting the need for further research.
Definitions
- Long COVID/PASC: A condition where individuals experience persistent symptoms following acute COVID-19 infection, often lasting for months.
- Fibrin amyloid microclots: Abnormal clots formed from fibrinogen that are resistant to breakdown, potentially contributing to vascular issues.
- Platelet hyperactivation: An increased state of platelet activity that can lead to excessive clotting and vascular complications.
AI simplified
Introduction
As approximately 30% of COVID-19 patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue, and in some cases begin, to suffer a variety of debilitating symptoms weeks or months after the acute phase of infection. The precise definition of this Long COVID/Post-Acute Sequelae of COVID-19 (PASC) (here referred to as Long COVID/PASC) is rather unclear and in some instances even vague. This is because most pathophysiological mechanisms involved have not yet been fully identified, and many different symptoms have been reported. The most frequently reported symptoms persist for 6 months or longer after acute infection [1]. COVID-19 survivors complain of recurring fatigue or muscle weakness, being out of breath, sleep difficulties, and suffer from anxiety or depression [2]. Symptoms noted in Long COVID/PASC patients show numerous similarities to those seen in chronic illnesses, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) [3 –8], Postural Orthostatic Tachycardia Syndrome [9] and Mast Cell Activation Syndrome [1, 10]. In a large global survey of 3762 Long COVID/PASC patients from 56 countries it was found that nearly half still could not work full-time 6 months post-infection, due mainly to fatigue, post-exertional malaise, and cognitive dysfunction [11].
An important component of severe COVID-19 disease is virus-induced endothelialiitis. This leads to disruption of normal endothelial function, initiating a state of failing normal clotting physiology. Massively increased levels of von Willebrand Factor (VWF) lead to overwhelming platelet activation, as well as activation of the enzymatic (intrinsic) clotting pathway. We have previously found persistent circulating fibrin amyloid microclots, that are resistant to fibrinolysis, in samples from acute COVID-19 patients [12, 13]. We also, for the first time, reported on the minor effect of clotting in a patient with the Omicron variant [14]. Endothelial, microclot and platelet pathologies are also present in Long COVID/PASC patients [15, 16]. In a recent study we identified numerous dysregulated molecules in circulation that might cause or reflect the lingering symptoms for those individuals with Long COVID/PASC [15]. We used proteomics to study the proteins present in both digested supernatant and trapped persistent pellet deposits (after protein digestion via trypsin). Dysregulated molecules include the acute phase inflammatory molecule Serum Amyloid A (SAA) and α(2)-antiplasmin (α2AP). We had previously discovered that in many chronic diseases fibrinogen can clot into an amyloid form that is resistant to fibrinolysis, and that these fibrin amyloid (micro)clots could be detected with a fluorogenic amyloid stain [12, 17 –24]. Thus, we used fluorescence microscopy to report large amyloid microclots and hyperactivated platelets present in blood samples from Long COVID/PASC; we also showed that these deposits are highly resistant to fibrinolysis [15, 25]. The plasmin-antiplasmin system plays a key role in blood coagulation and fibrinolysis [26]. Plasmin and α2AP are primarily responsible for a controlled and regulated dissolution of the fibrin polymers into soluble fragments such as d-dimer [26, 27]. We also developed a platelet and microclot grading system to classify platelet and microclot pathology [28]. The grading system should ideally be applied as part of a multi-pronged approach, which in addition to appropriate anticoagulation, may also include antiviral treatment to limit cell entry of SARS-CoV2.
Differentiation of platelet and microclot pathology due to Long COVID/PASC from cardiovascular disease (CVD), hypertension, hypercholesterolemia or diabetes as the main co-morbidities associated with SARS CoV-2 infection, is important in our search for ways to influence the underlying pathogenesis prophylactically. Many of the Long COVID/PASC symptoms that have been reported are related to symptoms that are cardio-pulmonary in nature. In this work we present results from a cohort of 845 patients who completed an online South African Long COVID/PASC registry. In parallel, blood samples of 80 patients who visited the clinical practice of our clinical co-author were collected to report on the presence of microclots and platelet pathology associated with persistent symptoms after recovery from acute COVID-19. Before contracting acute COVID-19, these patients did not suffer from fatigue and other symptoms that they subsequently reported, and which are typically associated with Long COVID/PASC. Thus, they were diagnosed as having Long COVID/PASC by means of eliminating all other common diseases, including heart failure.
Materials and methods
Ethical clearance
Ethics approval for the study was obtained from the Health Research Ethics Committee (HREC) of Stellenbosch University, South Africa, with references B21/03/001_COVID-19, project ID: #21911 (long COVID registry data) and N19/03/043, project ID #9521 (Long COVID blood collection). The experimental objectives, risks, and details were explained to volunteers and informed consent were obtained prior to blood collection. Strict compliance to ethical guidelines and principles of the Declaration of Helsinki, South African Guidelines for Good Clinical Practice, and Medical Research Council Ethical Guidelines for Research were kept for the duration of the study and for all research protocols.
Data collection and analysis of patients who filled in the South African Long COVID/PASC registry
The South African Long COVID/PASC registry is an online platform where patients can self-report long COVID/PASC symptoms and previous comorbidities. Data were analysed for risk factors associated with developing Long COVID/PASC. All data were anonymised. The statistical analysis of the South African Long COVID registry data was carried out in a Jupyter notebook environment [29] and the Pandas library [30] was employed for data manipulation and statistical analysis. With the aid of an interactive python data library, Plotly (https://plot.ly↗), visualisation of the statistical analysis was drawn using Sankey plots.
We have also used lattices (a technique based in knowledge representation and artificial intelligence) to visually represent the data. Lattices for exploratory data-science and artificial intelligence are less common than other techniques, but often yield different insights and paths for further exploration [31]. An introduction to lattices in exploratory data-science is given in [32] among others. The "conexp" software package (freely available from conexp.sourceforge.net) was used for preparing the lattices in this paper. The data of the 845 participants in the cohort were condensed into a single matrix mapping comorbidities to symptoms, in preparation for drawing the lattices. The input was a comma-separated values (CSV) file containing one patient per row, with entries of 0 or 1 (absence or presence) in columns, where the comorbidities and symptoms appear as individual columns. First, the percentage prevalence for each symptom was calculated by traversing all rows; this was subsequently used as a threshold vector. Next, for each comorbidity, the comorbidity-implied percentage prevalence was calculated for each symptom, giving a matrix of comorbidity (rows) versus symptoms (columns) and percentage entries. Finally, in order to draw easily visualised lattices with 0 and 1 entries, this last matrix was normalised based on the initially calculated threshold vector.
Blood sample collection from the cohort of 80 patients
Blood was drawn from 80 patients (35 females and 45 males); (mean/SD age 48 ± 16) who visited our clinical collaborator's practice. Either a qualified phlebotomist or medical practitioner drew citrated blood into sample tubes (BD Vacutainer®, 369714), via venepuncture, adhering to standard sterile protocol. Whole blood (WB) was centrifuged at 3000×g for 15 min at room temperature and the supernatant platelet poor plasma (PPP) samples were collected and stored in 1.5 mL Eppendorf tubes at − 80 °C, until the analysis was performed. Haematocrit samples were analysed on the day of collection.
Long COVID/PASC diagnosis
Patients gave consent to study their blood samples, following clinical examination. Participants who filled in the South African Long COVID/PASC registry, gave consent on the platform for the team to use their de-identified data. Symptoms must have been new and persistent symptoms noted after acute COVID-19. Initial patient diagnosis of the 80 participants who visited our clinical collaborator's practice (and who gave a blood sample), was the end result of exclusions, only after all other pathologies had been excluded. This was done by taking a history of previous symptoms (before and after acute COVID-19 infection), clinical examinations, and investigations including: full blood counts; N-terminal pro b-type natriuretic peptide (NTproBNP) levels (if raised it suggests cardiac damage); thyroid-stimulating hormone (TSH) and C-reactive protein levels. Lingering symptoms that can be ascribed to Long COVID/PASC were then assessed and included shortness of breath; recurring chest pain; lingering low oxygen levels; heart rate dysfunction (heart palpitations); constant fatigue (more than usual); joint and muscle pain; brain fog; lack of concentration; forgetfulness; sleep disturbances and digestive and kidney problems. These symptoms should have been persistent and new symptoms that were not present before acute COVID-19 infection and persistent for at least 2 months after recovery from acute (infective) COVID-19. This part of the examination was done only where the participants gave a blood sample.
Platelet pathology
Haematocrit samples of all 80 patients in the cohort were exposed to the two fluorescent markers, CD62P (PE-conjugated) (platelet surface P-selectin) (IM1759U, Beckman Coulter, Brea, CA, USA) and PAC-1 (FITC-conjugated) (340507, BD Biosciences, San Jose, CA, USA). CD62P is a marker for P-selectin that is either on the membrane of platelets or found inside them [13, 33]. PAC-1 identifies platelets through marking the glycoprotein IIb/IIIa (gpIIb/IIIa) on the platelet membrane. To study platelet pathology, 4 µL CD62P and 4 µL PAC-1 was added to 20 µL haematocrit, followed by incubation for 30 min (protected from light) at room temperature. The excitation wavelength band for PAC-1 was set at 450 to 488 nm and the emission at 499 to 529 nm and for the CD62P marker it was 540 nm to 570 nm and the emission 577 nm to 607 nm. Samples were viewed using a Zeiss Axio Observer 7 fluorescent microscope with a Plan-Apochromat 63x/1.4 Oil DIC M27 objective (Carl Zeiss Microscopy, Munich, Germany).
Platelet poor plasma (PPP) and the detection of amyloid fibrin(ogen) protein and anomalous microclotting
Microclot formation in PPP samples from all 80 Long COVID/PASC patients were analysed. These patients were diagnosed by our clinical collaborators, and they were not yet placed on any clinician-initiated treatment regimens. PPP were exposed to the fluorescent amyloid dye, Thioflavin T (ThT) (final concentration: 0,005mM) (Sigma-Aldrich, St. Louis, MO, USA) for 30 min (protected from light) at room temperature [20 –23]. After incubation, 3 µL PPP was placed on a glass slide and covered with a coverslip. The excitation wavelength band for ThT was set at 450 nm to 488 nm and the emission at 499 nm to 529 nm and processed samples were viewed using a Zeiss Axio Observer 7 fluorescent microscope with a Plan-Apochromat 63x/1.4 Oil DIC M27 objective (Carl Zeiss Microscopy, Munich, Germany) [12, 13, 25].
Results
South African Long COVID/PASC registry
Figure 1 gives a general overview of the South African Long COVID/PASC registry. About 10% (i.e. 87) of the participants were not initially tested for SARS-CoV2 using a PCR test, whereas in 90% (i.e. 758) of the patients, a COVID-19 positive test was reported. Moreover, patients were also categorised according to gender. Thus, 70% and 30% (i.e. 593 and 252) of the study cohort were identified as female and male, respectively, in line with common observations [34, 35]. The majority (i.e. 76%) of the participants were between the ages of 31–40, 41–50, and 51–60 years. We observed that participants with comorbidities such as high blood pressure, high cholesterol, type-2 diabetes, autoimmune disease, and previous blood clots were in the majority.
Figure 2 shows the gender distribution for the participants with the Long COVID/PASC symptoms in more detail. In a similar trend as observed in Fig. 2, the common Long COVID/PASC symptoms were noted as fatigue; brain fog, loss of concentration, and forgetfulness; shortness of breath, as well as joint and muscle pains. Interestingly, Long COVID/PASC symptoms such as kidney problems, digestive problems, and low oxygen levels were less commonly reported. Figure 3 shows the age versus Long COVID/PASC symptoms distribution of the participants. We note that the majority of participants were within the age ranges of 31–40, 41–50, and 51–60 years.
General overview of the population distribution of the South African Long COVID/PASC registry data as presented in a Sankey plot
Gender versus Long COVID/PASC symptoms population distribution of the South African Long COVID registry data
Age versus Long COVID/PASC symptoms participant distribution of the South African Long COVID/PASC registry data
A Sankey plot showing participants comorbidities versus Long COVID/PASC symptoms population distribution of the South African Long COVID registry data
Lattice plots, showing participants comorbidities versus Long COVID/PASC symptoms lattice, highlighting the high blood pressure and high cholesterol comorbidities A, B
![Fluorescence microscopy examples of the different stages of platelet activation and spreading, that was used to score the platelet activation in the Long COVID patients, with Stage 1, with minimally activated platelets, seen as small round platelets with a few pseudopodia, seen as healthy/control platelets that progresses to Stage 4, with egg-shaped platelets, are indicative of spreading and the beginning of clumping. Taken from [] with permission [28]](https://europepmc.org/articles/PMC9356426/bin/12933_2022_1579_Fig6_HTML.jpg "Click to view full size")
Fluorescence microscopy examples of the different stages of platelet activation and spreading, that was used to score the platelet activation in the Long COVID patients, with Stage 1, with minimally activated platelets, seen as small round platelets with a few pseudopodia, seen as healthy/control platelets that progresses to Stage 4, with egg-shaped platelets, are indicative of spreading and the beginning of clumping. Taken from [] with permission [28]
Blood analysis
Our overall platelet and microclot scoring results for 30 of the 80 patients were 7 ± 1.3, pointing to moderate activation.
![Fluorescence microscopy examples of the different stages of platelet clumping. With no clumping occurring in the healthy/control samples in Stage 1 (no figures shown), progressing to severe clumping of platelets as seen in Stage 4. Taken from [] with permission [28]](https://europepmc.org/articles/PMC9356426/bin/12933_2022_1579_Fig7_HTML.jpg "Click to view full size")
Fluorescence microscopy examples of the different stages of platelet clumping. With no clumping occurring in the healthy/control samples in Stage 1 (no figures shown), progressing to severe clumping of platelets as seen in Stage 4. Taken from [] with permission [28]
![Fluorescence microscopy showing microclots in platelet poor plasma (PPP) with representative examples of the different stages microclot formation. Stage 1 shows minimal microclot formation in healthy/control PPP which progresses to the presence of the severe microclotting Stage 4. The bottom row represents examples of stage 4 microclots using bright-field microscopy, fluorescence microscopy, and C an overlay of fluorescence and bright-field microscopy. A B Taken from [] with permission [28]](https://europepmc.org/articles/PMC9356426/bin/12933_2022_1579_Fig8_HTML.jpg "Click to view full size")
Fluorescence microscopy showing microclots in platelet poor plasma (PPP) with representative examples of the different stages microclot formation. Stage 1 shows minimal microclot formation in healthy/control PPP which progresses to the presence of the severe microclotting Stage 4. The bottom row represents examples of stage 4 microclots using bright-field microscopy, fluorescence microscopy, and C an overlay of fluorescence and bright-field microscopy. A B Taken from [] with permission [28]
Representative micrographs of hyperactivated platelets in individuals with Long COVID/PASC, with the arrows indicating mild platelet clumping
Representative micrographs of microclots in individuals with Long COVID/PASC. Moderate plasma microclots can be seen in the individuals with Long COVID/PASC
Microclots and platelets in two individuals with Long COVID/PASC. Representative micrographs of microclots in an untreated patient diagnosed with Long COVID/PASC, suffering from the condition for 11 months. The plasma was stained with thioflavin T (ThT); Platelet hyperactivation of the same patient, where PAC-1 and CD62PE were used to mark platelets. In this patient, cellular debris in the haematocrit was noted—here such cellular debris is shown in a tile scan., Microclot presence and platelets from a patient who was on self-administrated aspirin (anti-platelet) treatment before blood collection, where major microclots were noted, but the platelets were minimal hyperactivated, possibly due to the use of anti-platelet therapy A B C D E
| Score | Spreading | Score | Clumping |
|---|---|---|---|
| 1 | Activation with pseudopodia | 1 | None |
| 2 | Mild | 2 | Mild |
| 3 | Moderate | 3 | Moderate |
| 4 | Severe | 4 | Severe |
| Score | Analysis criteria |
|---|---|
| 1 | Very few areas of plasma protein misfolding (≤ 1 µm) visible with a few ≤ 10 µm microclots |
| 2 | Very few areas of plasma protein misfolding (≤ 1 µm) visible with scattered/mild ≤ 10 µm microclots |
| 3 | Moderate areas of plasma protein misfolding visible as microclots ≥ 15 µm |
| 4 | Severe areas of plasma protein misfolding visible as large microclots |
| Scoring results | |||
|---|---|---|---|
| Control/healthy | Mild | Moderate | Severe |
| = 3 | 4–7 | 8–10 | 11–12 |
Discussion
Here we report on the comorbidities and symptoms identified in a cohort of 845 South African Long COVID/PASC patients who filled in the South African Long COVID/PASC registry. We show that hypertension, high cholesterol levels (dyslipidaemia) and T2DM are important comorbidities that may play a significant role in the development of Long COVID/PASC in this cohort. (We also recognise that other comorbidities, such as previous viral infections, are also very important, but may manifest only in a larger cohort). It is well-documented that impaired endothelial function is associated with increased cholesterol and hypertension (which may be underpinned by generic variation) due to increased vascular oxidative stress and inflammation [36, 37]. Here we also showed the presence of fibrin amyloid microclotting and platelet pathologies in another cohort of 80 patients that visited a clinical practice complaining of persistent symptoms, where these patients were diagnosed with Long COVID/PASC. We found that in this cohort, all of the patients did indeed have both increased amyloid microclotting, as well as platelet pathologies, as assessed by a platelet and clotting grading system that we have developed previously [28].
Normal blood clotting goes through a variety of established mechanisms [33], a major step being the cleavage by thrombin of the complex fibrinogen molecule (roughly cylindrical, with a 5 × 45 nm size). This releases two fibrinopeptides, and causes the thermodynamically favourable formation of fibrin macrofibres, typically 50–100 nm in diameter. They may be crosslinked by Factor XIII. The clots are usually removed by fibrinolysis, leading to the residual formation of d-dimer; its normally low background levels reflect this background activity. It was always assumed that the normal conformation of a protein is that of its lowest free energy, as per Christian Anfinsen's famous protein refolding experiments. However, this is not the case. Many proteins can fold into a form of lower free energy but retain the identical sequence. Some of these forms, containing ordered beta-sheet structures, are generically referred to as amyloids, and many are well known to be associated with certain diseases. Ab in Alzheimer's disease and synuclein in Parkinson's disease are examples, with over 50 recognised [20]. Note, however, that almost any protein can form amyloid structures (e.g. recombinant insulin will do it over time, as will lysozyme held at an acid pH). Another well-known example of a class of proteins that can exist in two conformations of identical sequence is represented by prion proteins. The normal form with alpha-helices is called PrPc and the amyloid one PrPSc, the latter being of lower free energy i.e. more thermodynamically stable. It is also highly resistant to proteolysis. This transition between the two forms can itself be catalysed by the PrPSc. The key point of importance in microclot formation in Long COVID/PASC is that fibrin(ogen) too can, in the presence of various trigger substances, fold into an amyloid form that has a very different macrostructure characterised by different fibre diameters and pore sizes [38]. We noted for example that in type 2 Diabetes Mellitus (T2DM) clots have a netlike appearance [39 –42], while in Alzheimer's disease [18, 43 –45] and Parkinson's disease the fibres may be larger in size [17, 24]; they are also much more resistant to proteolysis [19], and are much more prevalent in the steady state.
We have been observing fibrin(ogen) changes generally for many years, initially via electron microscopy (e.g. [46 –51], and many others). Since 2011 we have also studied the effect of fibrin(ogen) folding in the presence of various inflammatory molecules, such as iron ions [52], that can stimulate the anomalous fibrin form [53]. These anomalous structures could also be found in a variety of disease states [19], such as T2DM [40] and Alzheimer's disease [54]. In this earlier literature we often referred to these anomalous clots as 'dense matted deposits'. In 2016, we showed that this anomalous resistance to fibrinolysis was because the anomalous structures were in fact amyloid in nature [38]. Such structures are easily observed under the optical microscope, and in particular may be stained with the fluorogenic dye thioflavin T and by the more recently developed oligothiophene dyes marketed by Ebba Biotech as Amytrackers [17, 21, 23].
![() After activation, platelets express P-selectin on their membranes, followed by platelet-T cell complex formation (); P-selectin on platelet membranes are also recognized by macrophages, possibly by the Fcγ-receptor; clearance may result due to either receptor binding or phagocytosis (). CD40L is released from platelets and can migrate to membranes or shed as soluble (s)CD40L (). sCD40L can bind to both the αβor CD40 receptors (). The P-selectin on the membranes of sCD40L-activated platelets can also form complexes with monocytes (). Platelet-neutrophils also form complexes (). 1 2 3 4 5 6 7 IIb 3 Diagram created with BioRender () and adapted from [] https://biorender.com/ [55]](https://europepmc.org/articles/PMC9356426/bin/12933_2022_1579_Fig12_HTML.jpg "Click to view full size")
() After activation, platelets express P-selectin on their membranes, followed by platelet-T cell complex formation (); P-selectin on platelet membranes are also recognized by macrophages, possibly by the Fcγ-receptor; clearance may result due to either receptor binding or phagocytosis (). CD40L is released from platelets and can migrate to membranes or shed as soluble (s)CD40L (). sCD40L can bind to both the αβor CD40 receptors (). The P-selectin on the membranes of sCD40L-activated platelets can also form complexes with monocytes (). Platelet-neutrophils also form complexes (). 1 2 3 4 5 6 7 IIb 3 Diagram created with BioRender () and adapted from [] https://biorender.com/ [55]
Conclusion
In the current study, we report data from the South African Long COVID Registry for the first time. It was noted that each of 80 patients diagnosed with Long COVID/PASC and who provided blood samples, showed platelet hyperactivation and microclot formation. We suggest that a platelet and clotting grading system should be used as a simple and cost-effective diagnostic method for the early identification of Long COVID/PASC. Diagnosis of Long COVID/PASC requires exclusion of other pathologies and evaluation of the duration of symptoms (> 2 months after acute infection). If a bleeding tendency (not seen commonly) is a concern, a TEG® can be used as a safety-net to not overtreat the patient. The exact combination of treatment and duration needs further investigation and testing in randomized control trials. Unfortunately, treatment protocols are not yet widely available and current protocols are based on clinician-initiated approaches and experience in managing these patients. No clinical trials have been performed yet; however, this will be an important next step to urgently consider in parallel to patient monitoring using a multi-modal pathology-supported genetic testing approach [56]. For implementation of personalised medicine it will be essential to bring together clinicians, researchers, patients and policy makers to advance healthcare while allowing for adjustment and flexibility in view of new discoveries [57]. The large number of affected individuals who develop Long COVID has major detrimental effects on public health and necessitates long-term follow-up and support that can be mediated via the Long COVID Registry as a major strength of this study.